BEAM compared with PACB: revenue, margins and what each company keeps, and the suppliers and customers both name

BEAMBeam Therapeutics Inc.

Mkt capRevenueRevenue

PACBPacific Biosciences of California, Inc.

Mkt capRevenueRevenue

Compare

BEAMBeam Therapeutics Inc.

PACBPacific Biosciences of California, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only BEAM 9

LLYEli Lillycustomer

PFEPfizercustomer

SANASana Biotechnologycustomer

PRMEPrime Medicinesupplier

5 more · BEAM chain ›

Shared 0

No shared counterparties.

Only PACB 2

—Illumina Cambridgeunlistedsupplier

—Buyerunlistedcustomer

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

BEAMBeam Therapeutics Inc.

27.24▼−5.55%· post 27.04

Mkt cap$2.8BRevenue$490,000Q2 FY26Revenue$140MFY25

PACBPacific Biosciences of California, Inc.

2.62▼−9.81%· post 2.60

ClosedOct 30 '26

Mkt cap$809.7MRevenue$39MQ2 FY26Revenue$160MFY25

Compare

ClosedOct 30 '26

BEAMBeam Therapeutics Inc.

PACBPacific Biosciences of California, Inc.

27.24▼−5.55%post 27.04

Price

2.62▼−9.81%post 2.60

$2.8B

Mkt cap

$809.7M

Q2 FY26$490,000

Revenue

$39MQ2 FY26

FY25$140M

Revenue

$160MFY25

BEAM27.24▼−5.55%vsPACB2.62▼−9.81%ClosedOct 30 '26